Blog Archives

The Importance of Getting Electronic Health Records Right: Another Way Your Health Data Is at Risk

Usually when we think of our personal health data being at risk, we think of things like dastardly hackers from far away countries or something far more mundane like a failure to have Health Insurance Portability and Accountability Act (HIPAA)

Tagged with: , , ,
Posted in Health & Law

Health Law Update Webinar – Thursday, July 21

Cozen O’Connor is hosting an in-person and webinar seminar on trending topics in health law on Thursday, July 21,  3:30 – 5:30 PM ET. I will be speaking on “Health Care Update from Washington: Rushing to the Finish Line Both

Posted in Uncategorized

Times They Are A-Changin’: Scope of Practice Finally Gets a Closer Look

No one should question the importance of medical training or ongoing educational requirements, nor should a health problem be addressed with anything but the expertise it requires. That said, far too often, health professionals (or perhaps more accurately their professional

Tagged with: , , , , , ,
Posted in Health & Law, Mental Health, Uncategorized

Section 1557 and Beyond: True Civil Rights Are Coming to Health Care at Long Last

I just watched the movie “All the Way,” an extraordinary account of LBJ’s first year in office and the passage of the Civil Rights Act of 1964. While that law was groundbreaking, many are surprised to learn it did relatively

Tagged with: , ,
Posted in Health & Law, Health Care Costs, Uncategorized

Understanding the Value of Medication: Whose job is it?

There has been a lot of discussion about drugs and drug pricing of late, including the idea of value-based purchasing.  One element, though, that hasn’t been getting quite enough attention is just how a patient or a pharmacist or a

Tagged with: , , , ,
Posted in Biosimilars, Health Care Costs, Pharmaceuticals

Drug Pricing: Where Are We Now?

Back in September, I mused that little was new in the drug pricing debate.  Today, while it is still true that novel solutions are not under discussion, there does seem to be new energy to the debate.  The issue has become

Tagged with: , , , ,
Posted in Health Care Costs, Pharmaceuticals

Is True Mental Health Parity Finally on the Horizon?

Nineteen years ago, the Mental Health Parity Act was signed into law.  It was a relatively small, but still important, step forward, making sure caps on mental health benefits were on par with those more medical/surgical health benefits.  Seven years

Tagged with: , , , , , , ,
Posted in Mental Health

What’s Old is New Again: Proposals to Rein in Drug Prices are Nothing New

It used to be that Americans would look the other way when it came to drug prices, concluding that the benefit outweighed the costs.  However, with prices continuing their march upward and with more of that price being borne directly

Tagged with: , , , , , , ,
Posted in Biosimilars, Health Care Costs, Pharmaceuticals

A Major Loss for Consumers: FDA Proposed Rule on Biosimilar Naming Threatens Savings and Offers No Gain in Safety

This morning’s proposed rule on biosimilar naming marks a major win for PhRMA and BIO and a loss for consumers, not to mention a reversal of FDA policy.  At a time when more than 70% of Americans believe drug companies

Tagged with: , , , , , ,
Posted in Biosimilars, Health Care Costs, Pharmaceuticals

True Public Service: A Moment of Appreciation for Frances Oldham Kelsey and Dedicated Countless Others at the FDA

Earlier this month Dr. Frances Oldham Kelsey passed away.  Although not a household name today, she became that rare thing: a civil servant who was not anonymous.  To the contrary, for a time, Dr. Kelsey was recognized by the public

Tagged with: , , , , , ,
Posted in Pharmaceuticals